
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Gyre Therapeutics Inc. (GYRE)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $19
1 Year Target Price $19
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.98% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 752.05M USD | Price to earnings Ratio 414 | 1Y Target Price 19 |
Price to earnings Ratio 414 | 1Y Target Price 19 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 6.11 - 19.00 | Updated Date 08/29/2025 |
52 Weeks Range 6.11 - 19.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate 0.02 | Actual 0.0022 |
Profitability
Profit Margin 4.08% | Operating Margin (TTM) 8.11% |
Management Effectiveness
Return on Assets (TTM) 4.27% | Return on Equity (TTM) 7.84% |
Valuation
Trailing PE 414 | Forward PE 48.78 | Enterprise Value 699073713 | Price to Sales(TTM) 7.36 |
Enterprise Value 699073713 | Price to Sales(TTM) 7.36 | ||
Enterprise Value to Revenue 6.84 | Enterprise Value to EBITDA 60.99 | Shares Outstanding 90826800 | Shares Floating 20459640 |
Shares Outstanding 90826800 | Shares Floating 20459640 | ||
Percent Insiders 87.16 | Percent Institutions 3.78 |
Upturn AI SWOT
Gyre Therapeutics Inc.

Company Overview
History and Background
Gyre Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for liver diseases. Founded in 2015, it has achieved milestones in preclinical and clinical development of its lead drug candidates. The company's evolution involves progressing therapies from research to late-stage clinical trials, seeking regulatory approvals, and establishing commercial partnerships.
Core Business Areas
- Drug Development: Focuses on researching, developing, and testing novel therapies for liver diseases, including NASH and liver fibrosis.
- Clinical Trials: Manages and conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Involves the marketing and sales of approved therapies through partnerships or internal commercial teams.
Leadership and Structure
The leadership team includes the CEO, CFO, CSO, and heads of clinical development and commercial operations. The organizational structure comprises research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Firsocostat: An investigational ACC inhibitor for the treatment of Non-Alcoholic SteatoHepatitis (NASH) with liver fibrosis. Currently in clinical trials. Market share is currently 0% as the product is not yet commercialized. Competitors include Madrigal Pharmaceuticals (resmetirom).
- Pyruvate Dehydrogenase Kinase (PDK) Inhibitors: A class of inhibitors for potential treatment of NASH. Currently in preclinical development. Market share is 0%. Competitors are emerging and are in early stages.
Market Dynamics
Industry Overview
The liver disease market is growing due to increasing prevalence of conditions like NASH, driven by obesity and diabetes. There is a high unmet need for effective therapies.
Positioning
Gyre Therapeutics Inc. is positioned as a player in the liver disease therapeutics market, focusing on NASH and liver fibrosis. Its competitive advantage lies in novel therapeutic targets and potential for improved efficacy.
Total Addressable Market (TAM)
The NASH market is projected to reach billions of dollars. Gyre is positioned to capture a share of the market once its drug candidates are approved and commercialized.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Strong preclinical and clinical data
- Experienced management team
- Potential for breakthrough therapies
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- Uncertainty of regulatory approval
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new liver disease indications
- Accelerated regulatory pathways
- Growing prevalence of NASH and liver fibrosis
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from novel therapies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDGL)
- Viking Therapeutics (VKTX)
- Intercept Pharmaceuticals (ICPT)
Competitive Landscape
Gyre is in the competitive landscape with larger and more established pharmaceutical companies. It's focused on new therapies for liver disease, specifically NASH and Liver Fibrosis
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing its drug candidates through preclinical and clinical development.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercial partnerships. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include advancing firsocostat through Phase 2/3 clinical trials and expanding its pipeline of PDK inhibitors.
Summary
Gyre Therapeutics Inc. is a biopharmaceutical firm focusing on novel liver disease treatments, particularly NASH. It demonstrates potential with its innovative therapeutic targets and ongoing clinical trials. Its financial constraints and dependence on clinical success pose notable risks, highlighting the importance of strategic partnerships and effective execution. However, the increasing demand for effective liver disease therapies presents a significant market opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share estimates are approximate and may vary. The AI-based rating is subjective and should be used as one factor among many when evaluating investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | Interim CEO & Executive Chair Mr. Ping Zhang | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.